Sign In
Buy ALIM
$5.54
+0 (+0%)
At Close: Dec 12, 2024
Mastercard Teams With Octet Europe For SMB Tech | PYMNTS.com
11:21pm, Friday, 12'th Jun 2020
Mastercard and Octet Europe rolled out a new trade system throughout the European Economic Area (EEA) to assist small- to medium-sized enterprises.
Mastercard Teams Up With Octet Europe to Launch New Trade Solution Across European Economic Area
02:04pm, Friday, 12'th Jun 2020
Mastercard announced on Thursday it has joined forces with Octet Europe to launch of a new trade solution across the European Economic Area (EEA). According to
State pension: Claimants aged 80 could get a boost of more than £80 a week – how to claim
06:49am, Friday, 12'th Jun 2020
STATE Pension can come in two forms, basic and new state pension. The basic state pension was replaced by new state pension in 2016 and it is being phased out but there are some people who may still b
How GDPR will be impacted by Brexit
10:23am, Thursday, 11'th Jun 2020
Ambiguity during this transitional period
Do Hedge Funds Love Alimera Sciences Inc (ALIM)?
10:04pm, Wednesday, 10'th Jun 2020
In this article we will take a look at whether hedge funds think Alimera Sciences Inc (NASDAQ:ALIM) is a good investment right now. We check hedge fund and billionaire investor sentiment before delvin
Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead
09:18am, Wednesday, 10'th Jun 2020
The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d
Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher
07:08am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M
Why the Opthea share price has skyrocketed 350% in the past year
05:44am, Wednesday, 10'th Jun 2020
The Opthea Ltd (ASX: OPT) share price has been a standout performer in the mid-cap ASX healthcare sector, up more than 350% in the past 12 months.
What's Opthea eyeing now that it has two successful trials under its belt? - Stockhead
03:44am, Wednesday, 10'th Jun 2020
Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema
Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon
02:49am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
12:16am, Wednesday, 10'th Jun 2020
Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph
Daiichi Sankyo’s SANTORINI Study Gets Underway, Investigating Cholesterol Care Across Europe
12:00am, Wednesday, 10'th Jun 2020
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced that the first patients have been enrolled in a multinational, prospective, o
Zurich Insurance : announces the successful placement of EUR 750 million of dated subordinated debt | MarketScreener
09:23pm, Tuesday, 09'th Jun 2020
Regulatory News: The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division
EC approves Elanco's purchase of Bayer animal health business
04:34pm, Monday, 08'th Jun 2020
$7.6 billion deal announced in August 2019; expected to be completed by mid-year 2020.
